Cedilla Therapeutics, a Cambridge, MA-based biotechnology company, raised $56.2m in Series A funding.
Third Rock Ventures made the investment.
Launched in 2018 by Third Rock Ventures and by Alexandra Glucksmann, Ph.D., president and chief executive officer, by Brian Jones, Ph.D., chief scientific officer, Cedilla is leveraging understanding of the principles that dictate protein stability to destabilize oncoprotein targets using a product engine that is also applicable to targets outside of oncology.
The company is building an integrated product engine to enhance endogenous degradation pathways.
– Direct ligand-induced degradation triggered by the binding of small molecules to target proteins
– Identification and disruption of stabilizing protein-protein interactions
– Discovery of upstream regulators that modulate the stability of target proteins
– Implementation of large-scale proteomics to map protein susceptibility
The management team also includes Andres Tellez, Ph.D., senior director of business and strategy; and Dale Porter, Ph.D., vice president and head of biology.
Cedilla’s scientific founders include:
– Alan D’Andrea, M.D., a professor at Harvard Medical School and director of the Center for DNA Damage and Repair at Dana-Faber Cancer Institute
– Steve Gygi, Ph.D., a professor of cell biology at Harvard Medical School
– Matthew Jacobson, Ph.D., a professor at the University of California, San Francisco School of Pharmacy
– William Kaelin, Jr., M.D., a professor at the Dana-Farber Cancer Institute and Harvard Medical School and investigator of the Howard Hughes Medical Institute
– Jack Taunton, Ph.D., a professor at the University of California, San Francisco School of Medicine.